ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 50,000 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 50,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $12.31, for a total value of $615,500.00. Following the completion of the sale, the director now directly owns 210,346 shares of the company’s stock, valued at approximately $2,589,359.26. This trade represents a 19.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Laura Shawver also recently made the following trade(s):

• On Monday, January 6th, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $11.10, for a total transaction of $555,000.00.
• On Monday, December 2nd, Laura Shawver sold 97,244 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $13.56, for a total transaction of $1,318,628.64.
• On Wednesday, December 4th, Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.75, for a total transaction of $203,115.00.

ARS Pharmaceuticals Trading Up 1.7 %

NASDAQ:SPRY opened at $12.52 on Wednesday. The stock has a 50-day simple moving average of $12.44 and a 200 day simple moving average of $13.14. ARS Pharmaceuticals, Inc. has a 52-week low of $6.26 and a 52-week high of $18.51.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several hedge funds have recently made changes to their positions in SPRY. Rhumbline Advisers boosted its holdings in ARS Pharmaceuticals by 2.9% during the fourth quarter. Rhumbline Advisers now owns 65,163 shares of the company’s stock worth $687,000 after purchasing an additional 1,824 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of ARS Pharmaceuticals by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock valued at $217,000 after buying an additional 1,962 shares in the last quarter. nVerses Capital LLC acquired a new position in ARS Pharmaceuticals during the third quarter worth $30,000. Creative Planning raised its position in ARS Pharmaceuticals by 7.0% during the third quarter. Creative Planning now owns 35,263 shares of the company’s stock worth $511,000 after acquiring an additional 2,307 shares in the last quarter. Finally, HighTower Advisors LLC lifted its stake in ARS Pharmaceuticals by 18.2% in the third quarter. HighTower Advisors LLC now owns 28,310 shares of the company’s stock valued at $411,000 after acquiring an additional 4,369 shares during the last quarter. 68.16% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on SPRY. Leerink Partners boosted their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Raymond James boosted their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $30.00 target price on shares of ARS Pharmaceuticals in a report on Tuesday, October 8th. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, ARS Pharmaceuticals has a consensus rating of “Buy” and an average price target of $26.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.